Safety and efficacy of ghrelin agonist TZP-101 in relieving symptoms in patients with diabetic gastroparesis: A randomized, placebo-controlled study

Neurogastroenterology and Motility

Volumn 22, Issue 10, 2010, Pages

  Ejskjaer, N ^a   Dimcevski, G ^b   Wo, J ^c   Hellstrom P M ^d   Gormsen, L C ^a   Sarosiek, I ^e   Softeland E ^b   Nowak, T ^f   Pezzullo, J C ^g   Shaughnessy, L ^h   Kosutic, G ^h   McCallum, R ^e  

^a AARHUS UNIVERSITY   (Denmark)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF LOUISVILLE   (United States)

^d UPPSALA UNIVERSITY   (Sweden)

^e UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^f Saint John's Health System   (United States)

^g GEORGETOWN UNIVERSITY   (United States)

^h Tranzyme Pharma   (United States)

Author keywords

gastric motility; gastroparesis management; ghrelin

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; GHRELIN RECEPTOR AGONIST; PLACEBO; TZP 101; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AGED; ANOREXIA; ARTICLE; BACKACHE; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC GASTROPARESIS; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; HYPERGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SATIETY; SCORING SYSTEM; SINUS TACHYCARDIA; STOMACH FUNCTION DISORDER; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; VOMITING;

ADOLESCENT; ADULT; AGED; APPETITE; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ENDPOINT DETERMINATION; FEMALE; GASTROPARESIS; GHRELIN; HUMANS; MACROCYCLIC COMPOUNDS; MALE; MIDDLE AGED; QUESTIONNAIRES; SATIETY RESPONSE; VOMITING; YOUNG ADULT;

EID: 77956316577     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/j.1365-2982.2010.01519.x     Document Type: Article

References (39)

1. Horowitz M, O'Donovan D, Jones KL, Feinle C, Rayner CK, Samsom M. Gastric emptying in diabetes: clinical significance and treatment. Diabet Med 2002 19 : 177 194.
2. Talley NJ, Young L, Bytzer P et al. Impact of chronic gastrointestinal symptoms in diabetes mellitus on health-related quality of life. Am J Gastroenterol 2001 96 : 71 6.
3. Jung H, Choung R, Locke G et al. The incidence, prevalence, and outcomes of patients with gastroparesis in Olmsted County, Minnesota, from 1996 to 2006. Gastroenterology 2009 136 : 1225 1233.
4. Soykan I, Sivri B, Sarosiek I, Kiernan B, McCallum R. Demography, clinical characteristics, psychological and abuse profiles, treatment, and long-term followup of patients with gastroparesis. Dig Dis Sci 1998 43 : 2398 2404.
5. Kuo P, Rayner CK, Jones KL, Horowitz M. Pathophysiology and management of diabetic gastropathy: a guide for endocrinologists. Drugs 2007 67 : 1671 1687.
6. Ma J, Rayner CK, Jones KL, Horowitz M. Diabetic gastroparesis: diagnosis and management. Drugs 2009 69 : 971 986.
7. Hoogerwerf WA, Pasricha PJ, Kalloo AN, Schuster MM. Pain: the overlooked symptom in gastroparesis. Am J Gastroenterol 1999 94 : 1029 1033.
8. Abell T, McCallum R, Hocking M et al. Gastric electrical stimulation for medically refractory gastroparesis. Gastroenterology 2003 125 : 421 428.
9. Abrahamsson H. Severe gastroparesis: new treatment alternatives. Best Pract Res Clin Gastroenterol 2007 21 : 645 655.
10. Hejazi R, McCallum R. Treatment of refractory gastroparesis: gastric and jejunal tubes, botox, gastric electrical stimulation, and surgery. Gastrointest Endosc Clin N Am 2009 19 : 73 82.
11. Date Y, Kojima M, Hosoda H et al. Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. Endocrinology 2000 141 : 4255 4261.
12. Fukuda H, Mizuta Y, Isomoto H et al. Ghrelin enhances gastric motility through direct stimulation of intrinsic neural pathways and capsaicin-sensitive afferent neurones in rats. Scand J Gastroenterol 2004 39 : 1209 1214.
13. Binn M, Albert C, Gougeon A et al. Ghrelin gastrokinetic action in patients with neurogenic gastroparesis. Peptides 2006 27 : 1603 1606.
14. Murray CD, Martin NM, Patterson M et al. Ghrelin enhances gastric emptying in diabetic gastroparesis: a double blind, placebo controlled, crossover study. Gut 2005 54 : 1693 1698.
15. Tack J, Depoortere I, Bisschops R, Verbeke K, Janssens J, Peeters T. Influence of ghrelin on gastric emptying and meal-related symptoms in idiopathic gastroparesis. Aliment Pharmacol Ther 2005 22 : 847 853.
16. Cremonini F, Camilleri M, Vazquez Roque M et al. Obesity does not increase effects of synthetic ghrelin on human gastric motor functions. Gastroenterology 2006 131 : 1431 1439.
17. Vestergaard ET, Hansen TK, Gormsen LC et al. Constant intravenous ghrelin infusion in healthy young men: clinical pharmacokinetics and metabolic effects. Am J Physiol Endocrinol Metab 2007 292 : E1829 36.
18. Fraser G, HR H, Tannenbaum G. Pharmacological demarcation of the growth hormone, gut motility and feeding effects of ghrelin using a novel ghrelin receptor agonist. Endocrinol 2008 149 : 620 628.
19. Lasseter KC, Shaughnessy L, Cummings D et al. Ghrelin agonist (TZP-101): safety, pharmacokinetics and pharmacodynamic evaluation in healthy volunteers: a phase I, first-in-human study. J Clin Pharmacol 2008 48 : 193 202.
20. Wargin W, Thomas H, Clohs L et al. Contribution of protein binding to the pharmacokinetics of the ghrelin receptor agonist TZP-101 in healthy volunteers and adults with symptomatic gastroparesis: two randomized, double-blind studies and a binding profile study. Clin Drug Investig 2009 29 : 409 418.
21. Ejskjaer N, Vestergaard E, Hellstrom P et al. Ghrelin agonist (TZP-101) accelerates gastric emptying in adults with diabetes and symptomatic gastroparesis: an exploratory, randomized, placebo-controlled, double-blind study. Aliment Pharm Ther 2009 29 : 1179 1187.
22. Popescu I, Fleshner P, Pezzullo J, Charlton P, Kosutic G, Senagore A. The ghrelin agonist TZP-101 for management of postoperative ileus after partial colectomy: a randomized, dose-ranging, placebo-controlled clinical trial. Dis Colon Rectum 2009 53 : 126 134.
23. McCallum R, Dimcevski G, Wo J et al. Ghrelin Agonist (TZP-101) Improves Symptoms in Diabetic Patients With Gastroparesis. Presented at: Joint International Neurogastroenterology and Motility Meeting. Chicago, IL, 2009.
24. Revicki DA, Rentz AM, Dubois D et al. Gastroparesis Cardinal Symptom Index (GCSI): development and validation of a patient reported assessment of severity of gastroparesis symptoms. Qual Life Res 2004 13 : 833 844.
25. Feldman EL, Stevens MJ. Clinical testing in diabetic peripheral neuropathy. Can J Neurol Sci 1994 21 : S3 7.
26. Revicki DA, Camilleri M, Kuo B et al. Development and content validity of a Gastroparesis Cardinal Symptom Index daily diary. Aliment Pharmacol Ther 2009 30 : 670 680.
27. Berry DA. Bayesian statistics. Med Decis Making 2006 26 : 429 430.
28. West M, Harrison P. Bayesian Forecasting and Dynamic Models, 2nd edn. New York : Springer-Verlag, 1997.
29. Ayinala S, Batista O, Goyal A et al. Temporary gastric electrical stimulation with orally or PEG-placed electrodes in patients with drug refractory gastroparesis. Gastrointest Endosc 2005 61 : 455 461.
30. Jones KL, Russo A, Stevens JE, Wishart JM, Berry MK, Horowitz M. Predictors of delayed gastric emptying in diabetes. Diabetes Care 2001 24 : 1264 1269.
31. Stanghellini V, Tosetti C, Horowitz M et al. Predictors of gastroparesis in out-patients with secondary and idiopathic upper gastrointestinal symptoms. Dig Liver Dis 2003 35 : 389 396.
32. Kindt S, Dubois D, Van Oudenhove L et al. Relationship between symptom pattern, assessed by the PAGI-SYM questionnaire, and gastric sensorimotor dysfunction in functional dyspepsia. Neurogastroenterol Motil 2009 21 : 1183 e105.
33. Harrell SP, Studts JL, Dryden GW, Eversmann J, Cai L, Wo JM. A novel classification scheme for gastroparesis based on predominant-symptom presentation. J Clin Gastroenterol 2008 42 : 455 459.
34. Kitazawa T, De Smet B, Verbeke K, Depoortere I, Peeters TL. Gastric motor effects of peptide and non-peptide ghrelin agonists in mice in vivo and in vitro. Gut 2005 54 : 1078 1084.
35. Orkin RD, New DI, Norman D et al. Rapid desensitisation of the GH secretagogue (ghrelin) receptor to hexarelin in vitro. J Endocrinol Invest 2003 26 : 743 747.
36. Musial F, Klosterhalfen S, Enck P. Placebo responses in patients with gastrointestinal disorders. World J Gastroenterol 2007 13 : 3425 3429.
37. Talley NJ, Verlinden M, Geenen DJ et al. Effects of a motilin receptor agonist (ABT-229) on upper gastrointestinal symptoms in type 1 diabetes mellitus: a randomised, double blind, placebo controlled trial. Gut 2001 49 : 395 401.
38. Benedetti F, Pollo A, Lopiano L, Lanotte M, Vighetti S, Rainero I. Conscious expectation and unconscious conditioning in analgesic, motor, and hormonal placebo/nocebo responses. J Neurosci 2003 23 : 4315 4323.
39. Bernstein CN. The placebo effect for gastroenterology: tool or torment. Clin Gastroenterol Hepatol 2006 4 : 1302 1308.